Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 03/04/2019
Entire Document
 


Case 18-10518-KG     Doc 958     Filed 02/28/19     Page 9 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: January 1, 2019 - January 31, 2019

 

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.    
 $ USD ‘000s    As of March 11, 2018      As of January 31, 2019           

 

 Assets

         

    Current assets:

         

      Cash and cash equivalents

     $ 21,372          $ 26,471    

      Accounts receivable, net

     19,203          -    

      Inventory

     8,857          -    

      Prepaid expenses and other current assets

     6,868          6,628    

      Intercompany receivable(1)

     93,353          -    
  

 

 

 

    

 

 

 

 

    Total current assets

     149,653          33,099    

    Non-current assets:

         

      Property and equipment, net

     543          -    

      Investment in Subsidiary(1)

     19,000          -    

      Intangible assets

     66,566          0    

      Other long-term assets

     588          1,252    

      Restricted cash

     100          100    
  

 

 

 

    

 

 

 

 

 Total assets

     $ 236,450          $ 34,451    
  

 

 

 

    

 

 

 

 

 Liabilities and Stockholders’ Equity

         

    Current liabilities:

         

      Accounts payable (2)

     925          619    

      DIP loan

     -          -    

      Accrued expenses

     3,921          3,439    
  

 

 

 

    

 

 

 

 

    Total current liabilities:

     4,846          4,058    
  

 

 

 

    

 

 

 

 

    Total liabilities not subject to compromise

     4,846          4,058    

    Total liabilities subject to compromise

     110,381          244,659    

    Series Z preferred stock

     3,343          -    

 Stockholders’ equity (deficit)

     117,880          (214,266  
  

 

 

 

    

 

 

 

 

 Total liabilities and stockholders’ equity (deficit)

     $ 236,450          $ 34,451    
  

 

 

 

    

 

 

 

 

Notes:

 

(1) Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting. (2) Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.